Researchers survey Weight-Loss drug users to understand Real-World experiences

NCT ID NCT07154238

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 30 times

Summary

This study collects information through online surveys from about 2,500 adults in Australia, Germany, UAE, and Spain who have been prescribed injectable semaglutide for weight management. The goal is to understand their characteristics, treatment experiences, and changes in weight and quality of life. No new treatment or lab tests are involved; it is purely a research survey.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novo Nordisk Investigational Site

    Bad Oeynhausen, 32545, Germany

Conditions

Explore the condition pages connected to this study.